



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/689,200	10/20/2003	Deana J. Dicosimo	CL1747USNA	8649

23906 7590 03/24/2005

E I DU PONT DE NEMOURS AND COMPANY
LEGAL PATENT RECORDS CENTER
BARLEY MILL PLAZA 25/1128
4417 LANCASTER PIKE
WILMINGTON, DE 19805

EXAMINER

VOGEL, NANCY S

ART UNIT

PAPER NUMBER

1636

DATE MAILED: 03/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/689,200	Applicant(s) DICOSIMO ET AL.	
	Examiner Nancy T. Vogel	Art Unit 1636	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-40 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-40 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. ____. |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____. |

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claim 1, 5, 6, 7, 12, 13, drawn to a method for expression of a coding region of interest in a C1 metabolizing bacteria, using the promoter of the *nrtA* gene only, classified in class 435, subclass 69.1.
- II. Claims 1, 5, 6, 7, 12, 13, drawn to a method for expression of a coding region of interest in a C1 metabolizing bacteria, using the promoter of the *glnB* gene only, classified in class 435, subclass 69.1.
- III. Claims 2, 5, 6, 8, 13, drawn to a method for expression of a coding region of interest in a C1 metabolizing bacteria, using the promoter of the *glyoxII* gene, classified in class 435, subclass 69.1.
- IV. Claims 3, 5, 6, 9, 10, 13 drawn to a method for expression of a coding region of interest in a C1 metabolizing bacteria using the promoter of the *htpG* gene, classified in class 435 subclass 69.1.
- V. Claims 4, 5, 6, 11, 13, drawn to a method for expression of a coding region of interest in a C1 metabolizing bacteria using the promoter of the *moxF* gene only, classified in class 435, subclass 69.1.
- VI. Claims 4, 5, 6, 11, 13, 14, drawn to a method for expression of a coding region of interest in a C1 metabolizing bacteria using the promoter of the *hps* gene only, classified in class 435, subclass 69.1.

- VII. Claim 15, 16, 19, drawn to an isolated nucleic acid molecule encoding SEQ ID NO:2, or which is SEQ ID NO:1, i.e. *nrtA* gene, classified in class 536, subclass 23.1.
- VIII. Claims 15, 16, 20, drawn to an isolated nucleic acid molecule encoding SEQ ID NO:5, or which is SEQ ID NO: 4, i.e. *glynB* gene, classified in class 536, subclass 23.1.
- IX. Claims 17 and 18, drawn to a polypeptide encoded by SEQ ID NO:1, i.e. SEQ ID NO:2, classified in class 435, subclass 183.
- X. Claims 17 and 18, drawn to a polypeptide encoded by SEQ ID NO:4, ie. SEQ ID NO:5, classified in class 435 subclass 183.
- XI. Claims 21, 22, 25 drawn to an isolated nucleic acid molecule encoding SEQ ID NO:8, i.e. SEQ ID NO:7, the *glyoxII* gene, classified in class 536, subclass 23.1
- XII. Claim 23 and 24, drawn to the polypeptide encoded by SEQ ID NO:7, i.e. the polypeptide of SEQ ID NO:8, classified in class 435, subclass 183.
- XIII. Claims 26, 27 and 30, drawn to an isolated nucleic acid encoding SEQ ID NO:11, i.e. SEQ ID NO:10, the *htpG* gene, classified in class 536 , subclass 23.1.
- XIV. Claims 28 and 29, drawn to the polypeptide encoded by SEQ ID NO:10, i.e. SEQ ID NO:11, the htpG enzyme, classified in class 435, subclass 183

- XV. Claims 31, 32, 35, drawn to an isolated nucleic acid encoding the polypeptide of SEQ ID NO: 14, i.e. the SEQ ID NO:13, the *moxF* gene, classified in class 536, subclass 23.1.
- XVI. Claims 31, 32, 36, drawn to an isolated nucleic acid encoding the polypeptide of SEQ ID NO 17, i.e. the SEQ ID NO:16, the *hps* gene, classified in class 536, subclass 23.1.
- XVII. Claims 33 and 34, drawn to the polypeptide encoded by SEQ ID NO: 13, ie. the polypeptide of SEQ ID NO:14, i.e. the *moxF* enzyme, classified in class 435, subclass 183.
- XVIII. Claims 33 and 34, drawn to the polypeptide encoded by SEQ ID NO:16, ie the polypeptide of SEQ ID NO:17, the *hps* enzyme, classified in class 435, subclass 183.
- XIX. Claim 37, drawn to a promoter region which is SEQ ID NO:3, classified in class 536, subclass 24.1
- XX. Claim 37, drawn to a promoter region which is SEQ ID NO: 6, classified in class 536, subclass 24.1.
- XXI. Claim 38, drawn to a promoter region which is SEQ ID NO:9, classified in class 536, subclass 24.1.
- XXII. Claim 39, drawn to a promoter region which is SEQ ID NO:12, classified in class 536, subclass 24.1.
- XXIII. Claim 40, drawn to a promoter region which is SEQ ID NO:15, classified in class 536, subclass 24.1.

XXIV. Claim 40, drawn to a promoter region which is SEQ ID NO:18, classified in class 536, subclass 24.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions of Groups XIX-XXIV and I-VI, respectively are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in another materially different process, such as in a method of DNA hybridization, as a probe.

The products of Groups VII-XXIV, are chemically, biologically, and functionally distinct from each other and thus one does not render the other obvious. The product of each group is not needed to produce the products of the other groups (each of which can be isolated from cells or organisms, made synthetically, and/or are self-replicating without the need for the isolated products of the other groups). Therefore, the inventions of the groups are capable of supporting separate patents.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. Further more, especially in instances where the classifications are the same, the non-patent literature searches required for each of these inventions are not co-extensive, hence said searches would be burdensome. Therefore, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b),"


1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nancy T. Vogel whose telephone number is (571) 272-0780. The examiner can normally be reached on 7:00 - 3:30, Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, Ph.D. can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


NANCY VOGEL, PH.D.
PATENT EXAMINER